DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line

RTTNews | 542 days ago
DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line

(RTTNews) - Biopharmaceutical company DURECT Corp. (DRRX) announced Monday that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. (CRL) for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada.

Charles River Research Models & Services (RMS) sales and marketing teams will collaborate with DURECT to jointly market and commercialize the ALZET product line to existing and new customers over a multi-year period.

Charles River RMS will provide dedicated marketing resources and collaborate with DURECT to develop and roll out a broad range of sales and marketing initiatives for ALZET.

DURECT will remain responsible for manufacturing, marketing support, order fulfillment and customer billing.

read more
Charles River Laboratories Slashes FY24 Outlook - Update

Charles River Laboratories Slashes FY24 Outlook - Update

While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2024.
RTTNews | 386 days ago
Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates

Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates

While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) raised its adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2023, to reflect the strong first-quarter financial performance and expectations for the remainder of the year that are largely consistent with its initial outlook.
RTTNews | 840 days ago
Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss

Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss

While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2022, due primarily to headwinds associated with the CDMO business, foreign exchange, and interest expense due to the rising interest rate environment.
RTTNews | 1121 days ago
DURECT Appoints Timothy Papp As New CFO

DURECT Appoints Timothy Papp As New CFO

Biopharmaceutical company DURECT Corp. (DRRX) announced Tuesday the appointment of Timothy Papp as its Chief Financial Officer. Papp brings over 25 years of corporate finance experience to DURECT, including 15 years in the Biopharma sector.
RTTNews | 1150 days ago
Australian Market Swings To Modest Gains In Mid-market

Australian Market Swings To Modest Gains In Mid-market

The Australian stock market is swinging to modest gains in mid-market moves on Friday after opening in the red, extending the gains in the previous two sessions, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is staying below the 9,000 mark, with gains in energy and technology stocks partially offset by weakness in mining and financial stocks.
RTTNews | 2h 2min ago